Skip to main content
SpringerLink
Log in

Abatacept/immunosuppressants/ruxolitinib

Various toxicities following off-label use and lack of efficacy: 20 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Wang YM, et al. Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults. Transplantation 106: 412-419, No. 2, Feb 2022. Available from: URL: http://doi.org/10.1097/TP.0000000000003768

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abatacept/immunosuppressants/ruxolitinib. Reactions Weekly 1904, 15 (2022). https://doi.org/10.1007/s40278-022-13947-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-13947-8

Search

Navigation